F inally, we will be able to achieve sustained viral response (SVR) in patients chronically infected with hepatitis C virus (HCV) using several interferon-free, all-oral, short-course antiviral regimens. This is a welcome proposition, not only for patients, but also for all of our 'traditional' HCV treating practitioners, namely, gastroenterologists, hepatologists, infectious disease specialists and nurses. At first glance, the direct-acting antiviral agents (DAAs), including inhibitors of NS3/4A protease, NS5A, and both nucleoside and non-nucleoside NS5B polymerase inhibitors, the long list looks daunting. The concise review by Yau and Yoshida (1) (pages 445-451) in the current issue of the Journal summarizes the interferon-free regimens available now or in the near future. There are multiple DAA combinations with potent efficacy (>95% SVR rates), pan-genotypic coverage, high resistance, minimal side effects, and concurrently demonstrating favourable features of low pill burden, short treatment duration and few drug interactions. The pharmaceutical industry will attempt to package and market these DAA combinations for HCV in the simplest possible way, similar to what they did when the different combination regimens for the treatment of Helicobacter pylori were offered (2) . The optimal antiviral regimen will likely include a combination of an NS5B nucleotide polymerase inhibitor with either a second-generation NS3/4A protease inhibitor or NS5A replication complex inhibitor (1).
HCV is a major cause of liver cirrhosis and hepatocellular carcinoma worldwide. Although HCV is significantly more common than HIV/ AIDS among global populations, it tends to be less well recognized. Approximately 170 million people (~3% of the world's population) are chronically infected with HCV. By comparison, it is estimated that there are 40 million HIV carriers. In Canada, nearly 250,000 individuals are viremic with HCV (3). Over the next two decades, this cohort will require a 60% increase in total health care spending associated with HCV as result of developing cirrhosis and its complications. The lifetime cost of a Canadian patient with HCV infection (excluding antiviral treatments) is estimated to be $64,694 (3). Not surprisingly, most media coverage of these recent developments in HCV treatment has not focused on the high SVR rates but, rather, on cost (4). These regimens of DAA combinations will have a one-time cost between $50,000 and $120,000 for a course of HCV treatment. Although the price for HCV treatment with DAA combinations may be high, it is less than the cost of life-long therapies for suppression of HIV viral load with antiviral agents, or management of inflammatory bowel disease with biologic and immunosuppressive agents (5) .
We have come a long way since the discovery of HCV 25 years ago (6). The development of DAAs has revolutionized HCV treatment by offering real prospects for elimination of a chronic viral infection. It is unfortunate that HCV vaccine research has lagged. Vaccination will be an important cost-effective alternative or complementary tool for the global eradication of HCV, especially in developing countries. Despite the genetic and antigenic diversity of HCV, substantial progress has been made, yielding several candidates for trials in high-risk populations (7) . In these critical times, Canadian public health agencies should take a more prominent role in the management of HCV and also in research on public health policy, as advocated by the National CIHR Research Training Program in Hepatitis C (8) . Effective HCV screening remains the cornerstone for elimination of HCV in Canada. The Canadian Liver Foundation advocates testing for HCV among 'baby boomers' (9), the Canadian birth-cohort from 1945 to 1970. 'Test and treat' strategies need to be elucidated as part of our attempt to eliminate HCV in Canada.
The Canadian health care system needs to adjust quickly to make these high-priced HCV medications available for treating all HCVinfected subjects. Testing high-risk populations without treating them will not help. The Canadian experience with the introduction of the first-generation DAAs boceprevir and telaprevir exposes the slow bureaucracy at both the federal and provincial levels to bring HCV treatments to patients (Figure 1 ). The time from submission of application eDitoRial ©2014 Pulsus Group Inc. All rights reserved to Health Canada's Therapeutic Products Directorate to listing of boceprevir in provincial drug formularies took a median of 21 months (range 11 to 40 months); boceprevir is still not on the Newfoundland and Labrador drug formulary. For telaprevir, the time was a median of 21 months (range 15 to 40 months) and telaprevir is still not on the Manitoba drug formulary. In Canada, effective approaches to control costs for high-priced medications need to be developed and evaluated to ensure broad, equitable and appropriate use of these new interventions in an already stressed health care system. We hope these new HCV treatments reach those who need them most without resorting to political pressure and community mobilization.
